|Articles|March 10, 2023
- Pharmaceutical Executive: March 2023
- Volume 43
- Issue 3
Pharmaceutical Executive, March 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 2 years ago
Navigating Disruption in the Metapharma Eraover 2 years ago
Biopharma M&A: Year in Review, Ripples Aheadover 2 years ago
Balancing Pharma Hiring Practices in Good Times and Badover 2 years ago
Being KOL-Centric: More Meaningful Expert Engagementover 2 years ago
Food for Thought: Make Room for Multiple Opinionsover 2 years ago
The Pivot to Digitalover 2 years ago
More than Ever, Data Will Dictate Future Fortunesover 2 years ago
Generative AI’s Breakthrough Potential in Pharma Marketingover 2 years ago
The Challenge of Taking on Falsified Medicines in EuropeNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
